NeuroSense Therapeutics (NRSN) Short Interest Ratio & Short Volume $1.27 +0.02 (+1.60%) (As of 11/1/2024 ET) Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends NeuroSense Therapeutics Short Interest DataNeuroSense Therapeutics (NRSN) has a short interest of 235,700 shares, representing 1.62% of the float (the number of shares available for trading by the public). This marks a -23.32% decrease in short interest from the previous month. The short interest ratio (days to cover) is 0.9, indicating that it would take 0.9 days of the average trading volume of 266,598 shares to cover all short positions.Current Short Interest235,700 sharesPrevious Short Interest307,400 sharesChange Vs. Previous Month-23.32%Dollar Volume Sold Short$225,564.90Short Interest Ratio0.9 Days to CoverLast Record DateOctober 15, 2024Outstanding Shares13,670,000 sharesFloat Size14,550,000 sharesShort Percent of Float1.62%Today's Trading Volume492,412 sharesAverage Trading Volume266,598 sharesToday's Volume Vs. Average185% Short Selling NeuroSense Therapeutics? Sign up to receive the latest short interest report for NeuroSense Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNRSN Short Interest Over TimeNRSN Days to Cover Over TimeNRSN Percentage of Float Shorted Over Time Ad Crypto 101 MediaCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Click here to reserve your spot at the emergency crypto summit now. NeuroSense Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/15/2024235,700 shares $225,564.90 -23.3%1.6%0.9 $0.96 9/30/2024307,400 shares $390,398.00 -20.3%2.1%1 $1.27 9/15/2024385,600 shares $520,560.00 -18.1%2.7%1 $1.35 8/31/2024470,700 shares $418,923.00 +236.2%3.3%1.2 $0.89 8/15/2024140,000 shares $103,600.00 +73.7%1.0%0.5 $0.74 7/31/202480,600 shares $61,239.88 -44.8%0.6%0.3 $0.76 Get the Latest News and Ratings for NRSN and Related StocksEnter your email address below to receive the latest news and analysts' ratings for NeuroSense Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 7/15/2024146,000 shares $134,918.60 +715.6%1.1%0.6 $0.92 6/30/202417,900 shares $20,048.00 +121.0%0.1%0.1 $1.12 6/15/20248,100 shares $7,857.00 -17.4%0.1%0.1 $0.97 5/31/20249,800 shares $10,584.00 -52.4%0.1%0.1 $1.08 5/15/202420,600 shares $24,678.80 +13.2%0.2%0.1 $1.20 4/30/202418,200 shares $24,570.00 -79.4%0.2%0.1 $1.35 4/15/202488,400 shares $135,252.00 +38.8%0.8%0.3 $1.53 3/31/202463,700 shares $115,934.00 +81.5%0.7%0.2 $1.82 3/15/202435,100 shares $48,438.00 -83.4%0.4%0.1 $1.38 2/29/2024211,400 shares $374,178.00 +42.0%2.3%0.5 $1.77 2/15/2024148,900 shares $198,037.00 +12.7%1.6%0.2 $1.33 1/31/2024132,100 shares $165,125.00 -35.6%1.5%0.2 $1.25 1/15/2024205,200 shares $175,261.32 -17.7%2.3%0.2 $0.85 12/31/2023249,200 shares $195,622.00 +18.7%2.7%0.3 $0.79 12/15/2023210,000 shares $176,631.00 +1.9%2.3%0.2 $0.84 11/30/2023206,100 shares $265,869.00 -11.9%2.3%0.3 $1.29 11/15/2023234,000 shares $120,276.00 +89.3%2.6%1 $0.51 10/31/2023123,600 shares $56,930.16 +182.2%1.4%0.6 $0.46 10/15/202343,800 shares $23,956.67 +91.3%0.5%0.3 $0.55 9/30/202322,900 shares $16,259.00 -3.8%0.3%0.3 $0.71 9/15/202323,800 shares $20,944.00 +9.2%0.3%0.6 $0.88 8/31/202321,800 shares $20,492.00 +77.2%0.2%0.5 $0.94 8/15/202312,300 shares $11,808.00 -37.6%0.1%0.2 $0.96 7/31/202319,700 shares $25,610.00 -53.4%0.3%0.3 $1.30 7/15/202342,300 shares $57,528.00 -38.3%0.6%0.5 $1.36 6/30/202368,600 shares $102,214.00 -12.4%1.0%0.9 $1.49 6/15/202378,300 shares $144,072.00 -38.8%1.2%1 $1.84 5/31/2023127,900 shares $199,524.00 -13.6%1.9%1.9 $1.56 5/15/2023148,000 shares $253,080.00 -1.7%2.2%2.9 $1.71 4/30/2023150,600 shares $304,212.00 -12.0%2.2%2 $2.02 4/15/2023171,100 shares $278,893.00 -8.2%2.5%1.4 $1.63 3/31/2023186,300 shares $320,436.00 -6.1%2.8%0.1 $1.72 3/15/2023198,300 shares $354,957.00 -6.4%3.1%0.1 $1.79 2/28/2023211,800 shares $393,948.00 -10.1%3.1%0.2 $1.86Elon knows the truth, which is why they want him silenced (Ad)Elon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to humanity, there is a war being waged on Elon Musk. This war has nothing to do with X, Elon’s stance on immigration or his support for Donald Trump. Watch this new documentary and you’ll discover what Elon knows, 2/15/2023235,700 shares $393,619.00 +8.2%3.4%0.2 $1.67 1/31/2023217,900 shares $337,745.00 +1,479.0%3.2%0.2 $1.55 1/15/202313,800 shares $18,630.00 -25.0%0.2%0 $1.35 12/30/202218,400 shares $22,448.00 -24.6%0.3%0.7 $1.22 12/15/202224,400 shares $37,332.00 -22.0%0.4%0.8 $1.53 11/30/202231,300 shares $53,836.00 +30.4%0.5%0.9 $1.72 11/15/202224,000 shares $40,800.00 -21.8%0.4%0.6 $1.70 10/31/202230,700 shares $49,120.00 -40.0%0.5%0.8 $1.60 10/15/202251,200 shares $87,552.00 -53.7%0.7%0.7 $1.71 9/30/2022110,500 shares $197,795.00 +269.6%1.6%1.1 $1.79 9/15/202229,900 shares $61,893.00 +13.7%0.4%0 $2.07 8/31/202226,300 shares $51,285.00 -46.8%0.4%0 $1.95 8/15/202249,400 shares $111,150.00 +31.4%0.8%0 $2.25 7/31/202237,600 shares $70,312.00 -36.5%0.6%0 $1.87 7/15/202259,200 shares $121,952.00 -91.8%0.9%0 $2.06 6/30/2022719,900 shares $2.43 million +302.4%11.7%0.2 $3.38 6/15/2022178,900 shares $305,919.00 +1.6%2.9%0.2 $1.71 5/31/2022176,100 shares $248,301.00 +78.8%2.9%0 $1.41 5/15/202298,500 shares $125,095.00 +64.2%1.6%0 $1.27 4/30/202260,000 shares $100,800.00 +26.3%1.0%0 $1.68 4/15/202247,500 shares $95,950.00 -86.3%N/A0 $2.02 3/31/2022347,000 shares $1.38 million +568.6%5.7%0.1 $3.97 3/15/202251,900 shares $72,660.00 +464.1%0.9%0 $1.40 2/28/20229,200 shares $23,920.00 +187.5%0.2%0 $2.60 2/15/20223,200 shares $5,568.00 -38.5%0.1%0 $1.74 1/31/20225,200 shares $10,244.00 -80.4%0.1%0 $1.97 1/15/202226,500 shares $72,875.00 +69.9%0.4%0.1 $2.75 12/31/202115,600 shares $38,376.00 No Change0.3%0 $2.46 NRSN Short Interest - Frequently Asked Questions What is NeuroSense Therapeutics' current short interest? Short interest is the volume of NeuroSense Therapeutics shares that have been sold short but have not yet been closed out or covered. As of October 15th, investors have sold 235,700 shares of NRSN short. 1.62% of NeuroSense Therapeutics' shares are currently sold short. Learn More on NeuroSense Therapeutics' current short interest. What is a good short interest ratio for NeuroSense Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. NRSN shares currently have a short interest ratio of 1.0. Learn More on NeuroSense Therapeutics's short interest ratio. What is a good short interest percentage for NeuroSense Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.62% of NeuroSense Therapeutics' floating shares are currently sold short. Is NeuroSense Therapeutics' short interest increasing or decreasing? NeuroSense Therapeutics saw a decrease in short interest during the month of October. As of October 15th, there was short interest totaling 235,700 shares, a decrease of 23.3% from the previous total of 307,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is NeuroSense Therapeutics' float size? NeuroSense Therapeutics currently has issued a total of 13,670,000 shares. Some of NeuroSense Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. NeuroSense Therapeutics currently has a public float of 14,550,000 shares. How does NeuroSense Therapeutics' short interest compare to its competitors? 1.62% of NeuroSense Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to NeuroSense Therapeutics: ALX Oncology Holdings Inc. (31.74%), Verrica Pharmaceuticals Inc. (17.38%), Spero Therapeutics, Inc. (0.72%), Citius Pharmaceuticals, Inc. (6.87%), RAPT Therapeutics, Inc. (8.22%), Onconetix, Inc. (0.31%), Syros Pharmaceuticals, Inc. (4.82%), Eupraxia Pharmaceuticals Inc. (0.39%), Connect Biopharma Holdings Limited (0.09%), Gain Therapeutics, Inc. (2.36%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.14 billion), AppLovin Co. ($3.15 billion), Paychex, Inc. ($2.69 billion), Nu Holdings Ltd. ($2.48 billion), Cencora, Inc. ($2.24 billion), International Paper ($2.04 billion), Tractor Supply ($1.96 billion), Coinbase Global, Inc. ($1.93 billion), Moderna, Inc. ($1.91 billion), and SoFi Technologies, Inc. ($1.84 billion). View all of the most shorted stocks. What does it mean to sell short NeuroSense Therapeutics stock? Short selling NRSN is an investing strategy that aims to generate trading profit from NeuroSense Therapeutics as its price is falling. NRSN shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against NeuroSense Therapeutics? A short squeeze for NeuroSense Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of NRSN, which in turn drives the price of the stock up even further. How often is NeuroSense Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NRSN, twice per month. The most recent reporting period available is October, 15 2024. More Short Interest Resources from MarketBeat Related Companies ALX Oncology Short Interest Data Verrica Pharmaceuticals Short Interest Data Spero Therapeutics Short Interest Data Citius Pharmaceuticals Short Interest Data RAPT Therapeutics Short Interest Data Onconetix Short Interest Data Syros Pharmaceuticals Short Interest Data Eupraxia Pharmaceuticals Short Interest Data Connect Biopharma Short Interest Data Gain Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:NRSN) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | SponsoredWall St. Legend: Millions of Americans About to Fall Out of the 1%Wall Street insider reveals the financial tidal wave about to knock millions of Americans out of the One Perce...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NeuroSense Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share NeuroSense Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.